Research Article
PDF Mendeley EndNote BibTex Cite

D vitamini düzeyi ile paraoksonaz 1 enzim aktivitesi arasındaki ilişki

Year 2019, Volume 33, Issue 3, 199 - 206, 06.02.2020
https://doi.org/10.5505/deutfd.2019.63644

Abstract

Amaç: D vitamini eksikliği lipid metabolizması üzerine olumsuz etki oluşturmakta ve kardiyovasküler riski artırmaktadır. Paraoksonaz-1 (PON1) enzim aktivitesi, yüksek dansiteli lipoprotein (HDL) aktivitesini belirleyen faktörlerden birisidir. Bu araştırmada, D vitamin düzeyi ile PON1 aktivitesi arasında ilişkili olup olmadığının incelenmesi amaçlandı. Gereç ve Yöntem: Çalışmamıza 18-50 yaş arası, benzer demografik özelliklere sahip 200 sağlıklı birey alındı. Araştırmaya dahil edilen bireyler serum 25(OH)D vitamini düzeyine göre D vitamini düzeyi normal (>30 ng/dL), D vitamin eksikliği olan (20-30 ng/dL), D vitamin yetmezliği olan (10-20 ng/dL) ve derin D vitamin yetmezliği olan (<10 ng/dL) bireyler olarak 4 gruba ayrıldı. Bu dört grup arasında PON1 enzim aktivitesi düzeyi karşılaştırıldı. Plazma PON1 enzim aktivitesi ELISA yöntemi ile ölçüldü. Bulgular: Araştırmamıza dahil olan bireylerin 132’si kadın ve 68’i erkek idi. PON1 enzim aktivitesi 4 grup arasında istatistiksel anlamlı bir fark oluşturmadı. Ayrıca PON1 enzim aktivitesi ile diğer parametreler arasında da herhangi bir ilişki saptanmadı. Sonuç: D vitamini düzeyi ile PON1 enzim aktivitesi arasında bir ilişki saptanmadı.

References

  • 1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.
  • 2. Mozos I, Marginean O. Links between Vitamin D deficiency and cardiovascular diseases. Biomed Res Int. 2015;2015:109275.
  • 3. Reid IR, Bolland MJ. Role of vitamin D deficiency in cardiovascular disease. Heart. 2012;98(8):609–14.
  • 4. Lavie CJ, Lee JH, Milani R V. Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol. 2011;58(15):1547–56.
  • 5. Sahota O. Understanding vitamin D deficiency. Age Ageing. 2014;43(5):589–91.
  • 6. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50(4):303–12.
  • 7. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.
  • 8. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14.
  • 9. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation. 2013;128(23):2517–31.
  • 10. Thomas GN, Hartaigh BÓ, Bosch JA, Pilz S, Loerbroks A, Kleber ME, et al. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: The Ludwigshafen risk and cardiovascular health (LURIC) study. Diabetes Care. 2012;35(5):1158–64.
  • 11. Uysal S, Akyol S, Hasgül R, Armutcu F, Yiğitoğlu F. Çok Yönlü Bir Enzim: Paraoksonaz. Yeni Tıp Derg. 2011;28(3):136–41.
  • 12. Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP. Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders. Int J Mol Sci. 2019;20(16):pii: E4049.
  • 13. Tarcin O. Paraoxonase-1 And Coronary Heart Diseases. Marmara Med J. 2010;24(1):59–63.
  • 14. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. J Biol Chem. 2001;354:1–7.
  • 15. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, et al. Apolipoprotein A-I Promotes the Formation of Phosphatidylcholine Core Aldehydes that Are Hydrolyzed by Paraoxonase (PON-1) during High Density Lipoprotein Oxidation with a Peroxvnitrite Donor. J Biol Chem. 2001;276(27):24473.
  • 16. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem. 2000;275(6):3957–62.
  • 17. Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact. 2016;259:51–62.
  • 18. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004;107(5):435–47.
  • 19. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69(4):541–50.
  • 20. Marchegiani F, Marra M, Olivieri F, Cardelli M, James RW, Boemi M, et al. Paraoxonase 1: Genetics and Activities During Aging. Rejuvenation Res. 2008;11:113–27.
  • 21. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775–9.
  • 22. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arter Thromb Vasc Biol. 1999;19:330–5.
  • 23. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775–9.
  • 24. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arter Thromb Vasc Biol. 1999;19:330–5.
  • 25. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol. 2004;15:399–404.
  • 26. Kıdır V. D Vitamininin kardiyovasküler ve metabolik etkileri. J Clin Exp Invest. 2013;4(3):398–404.
  • 27. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998;31(3):329–36.
  • 28. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005;90(3):1728–3.
  • 29. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97(7):1630–9.
  • 30. Kotur-Stevuljević J, Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, et al. Paraoxonase 1 and atherosclerosis-related diseases. Biofactors. 2019;
  • 31. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963–8.
  • 32. C. Brewer L, D. Michos E, P. Reis J. Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function. Curr Drug Targets. 2011;12:54–60.
  • 33. Mutt SJ, Jokelainen J, Sebert S, Auvinen J, Järvelin MR, Keinänen-Kiukaanniemi S, et al. Vitamin D status and components of metabolic syndrome in older subjects from Northern Finland (Latitude 65◦North). Nutrients. 2019;11(6):pii: E1229.
  • 34. Motiwala SR, Wang TJ. Vitamin D and cardiovascular disease. Curr Opin Nephrol Hyperten. 2011;20(4):345–53.
  • 35. Zhou C, Cao J, Shang L, Tong C, Hu H, Wang H, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis Markers. 2013;35(2):97–103.
  • 36. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004;107(5):435–47.

RELATIONSHIP BETWEEN VITAMIN D LEVEL AND PARAOXONASE 1 ENZYME ACTIVITY

Year 2019, Volume 33, Issue 3, 199 - 206, 06.02.2020
https://doi.org/10.5505/deutfd.2019.63644

Abstract

Objective: Vitamin D deficiency has a negative effect on lipid metabolism and increases cardiovascular risk. Paraoxonase-1 (PON1) enzyme activity is one of the determinants of high-density lipoprotein (HDL) activity. The aim of this study was to investigate whether vitamin D level and PON1 activity are related. Material and Method: 200 healthy individuals between 18-50 years of age with similar demographic characteristics were included. Individuals included in the study were divided into four groups as vitamin D levels: sufficient (>30 ng/dL), mild-moderate deficiency (20-30 ng/dL), deficiency (10-20 ng/dL) and severe deficiency (<10 ng/dL). PON1 enzyme activity of these four groups was compared. Plasma PON1 enzyme activity was measured by ELISA. Results: Of the individuals included to this study, 132 were female and 68 were male. PON1 enzyme activity did not show any statistically significant difference between these 4 groups. There was not any relationship between PON1 enzyme activity and other parameters. Conclusion: There was no relationship between vitamin D levels and PON1 enzyme activity.

References

  • 1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.
  • 2. Mozos I, Marginean O. Links between Vitamin D deficiency and cardiovascular diseases. Biomed Res Int. 2015;2015:109275.
  • 3. Reid IR, Bolland MJ. Role of vitamin D deficiency in cardiovascular disease. Heart. 2012;98(8):609–14.
  • 4. Lavie CJ, Lee JH, Milani R V. Vitamin D and cardiovascular disease will it live up to its hype? J Am Coll Cardiol. 2011;58(15):1547–56.
  • 5. Sahota O. Understanding vitamin D deficiency. Age Ageing. 2014;43(5):589–91.
  • 6. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50(4):303–12.
  • 7. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–11.
  • 8. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14.
  • 9. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation. 2013;128(23):2517–31.
  • 10. Thomas GN, Hartaigh BÓ, Bosch JA, Pilz S, Loerbroks A, Kleber ME, et al. Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: The Ludwigshafen risk and cardiovascular health (LURIC) study. Diabetes Care. 2012;35(5):1158–64.
  • 11. Uysal S, Akyol S, Hasgül R, Armutcu F, Yiğitoğlu F. Çok Yönlü Bir Enzim: Paraoksonaz. Yeni Tıp Derg. 2011;28(3):136–41.
  • 12. Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP. Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders. Int J Mol Sci. 2019;20(16):pii: E4049.
  • 13. Tarcin O. Paraoxonase-1 And Coronary Heart Diseases. Marmara Med J. 2010;24(1):59–63.
  • 14. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. J Biol Chem. 2001;354:1–7.
  • 15. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, et al. Apolipoprotein A-I Promotes the Formation of Phosphatidylcholine Core Aldehydes that Are Hydrolyzed by Paraoxonase (PON-1) during High Density Lipoprotein Oxidation with a Peroxvnitrite Donor. J Biol Chem. 2001;276(27):24473.
  • 16. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem. 2000;275(6):3957–62.
  • 17. Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact. 2016;259:51–62.
  • 18. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004;107(5):435–47.
  • 19. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69(4):541–50.
  • 20. Marchegiani F, Marra M, Olivieri F, Cardelli M, James RW, Boemi M, et al. Paraoxonase 1: Genetics and Activities During Aging. Rejuvenation Res. 2008;11:113–27.
  • 21. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775–9.
  • 22. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arter Thromb Vasc Biol. 1999;19:330–5.
  • 23. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775–9.
  • 24. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arter Thromb Vasc Biol. 1999;19:330–5.
  • 25. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol. 2004;15:399–404.
  • 26. Kıdır V. D Vitamininin kardiyovasküler ve metabolik etkileri. J Clin Exp Invest. 2013;4(3):398–404.
  • 27. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998;31(3):329–36.
  • 28. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005;90(3):1728–3.
  • 29. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97(7):1630–9.
  • 30. Kotur-Stevuljević J, Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, et al. Paraoxonase 1 and atherosclerosis-related diseases. Biofactors. 2019;
  • 31. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963–8.
  • 32. C. Brewer L, D. Michos E, P. Reis J. Vitamin D in Atherosclerosis, Vascular Disease, and Endothelial Function. Curr Drug Targets. 2011;12:54–60.
  • 33. Mutt SJ, Jokelainen J, Sebert S, Auvinen J, Järvelin MR, Keinänen-Kiukaanniemi S, et al. Vitamin D status and components of metabolic syndrome in older subjects from Northern Finland (Latitude 65◦North). Nutrients. 2019;11(6):pii: E1229.
  • 34. Motiwala SR, Wang TJ. Vitamin D and cardiovascular disease. Curr Opin Nephrol Hyperten. 2011;20(4):345–53.
  • 35. Zhou C, Cao J, Shang L, Tong C, Hu H, Wang H, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis Markers. 2013;35(2):97–103.
  • 36. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004;107(5):435–47.

Details

Primary Language Turkish
Subjects Medicine
Journal Section Research Articles
Authors

Özge DOKUZLAR This is me
DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ, GERİATRİ ANABİLİM DALI
0000-0001-7079-9696
Türkiye


Mehmet CALAN This is me
İzmir Bozyaka Eğitim ve Araştırma Hastanesi Endokrinoloji Kliniği
0000-0002-5614-0710
Türkiye


Ali ŞİŞMAN This is me
DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ, TEMEL TIP BİLİMLERİ BÖLÜMÜ, TIBBİ BİYOKİMYA ANABİLİM DALI
0000-0002-9266-0844
Türkiye


Sinem KOCAER This is me
DOKUZ EYLÜL ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, ROMATOLOJİ BİLİM DALI
0000-0002-5481-0776
Türkiye


Fırat BAYRAKTAR This is me (Primary Author)
ENDOKRİN VE METABOLİZMA HASTALIKLARI BİLİM DALI
0000-0001-7800-2530
Türkiye

Publication Date February 6, 2020
Application Date May 14, 2019
Acceptance Date September 3, 2019
Published in Issue Year 2019, Volume 33, Issue 3

Cite

Vancouver Dokuzlar Ö. , Calan M. , Şişman A. , Kocaer S. , Bayraktar F. D vitamini düzeyi ile paraoksonaz 1 enzim aktivitesi arasındaki ilişki. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi. 2020; 33(3): 199-206.